Dauntless Pharmaceuticals, Inc.

The Biotechnology Innovation Organization (BIO) has submitted comments to the US Department of the Treasury about proposed foreign investment regulations that the trade group believes will prevent for

Cleave Biosciences Inc. has raised a $37m Series B round to fund two ongoing Phase I clinical trials for its lead drug candidate CB-5083, initiate a third trial, and to continue its hunt for therape

IN VITRO DIAGNOSTICS 23andMe Inc. 23andMe completes $150mm Series E financing 23andMe Inc. , which sells DNA testing kits directly to consumers who contribute their data to large-scale genetic